OSLO, Norway, Aug. 14, 2024 (GLOBE NEWSWIRE) — Nykode Therapeutics ASA (OSE: NYKD ), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced that the United States Patent and Trademark Office. (USPTO) has issued US Patent No. 12,059,459, entitled, Therapeutic Anticancer Neoepitope Vaccine.
A newly issued patent describes Nykode’s individual neoantigen-based vaccine, VB10.NEO, which is being developed for the treatment of advanced or metastatic solid tumors. The 20-year expiration date of this patent is January 5, 2037. Related patents were previously granted to companies in Russia, India, and Australia.
Michael Engsig, CEO of Nykode, said, We are very pleased with the granting of this important patent in the US, a key market for Nykode. Continuing to develop patent protection is a core strategy for us. The granting of this patent is a testament to the world-class innovation carried out in the Nykode laboratory. We remain dedicated to pushing the boundaries of what is possible in medicine, bringing hope to patients and their families around the world.
About VB10.NEO
VB10.NEO is an individualized neoantigen vaccine developed for the treatment of locally advanced or metastatic solid tumors in an exclusive worldwide clinical collaboration with Genentech, a member of the Roche Group. This vaccine is designed to be produced on-demand according to the neoantigen profile of the individual patient. Neoantigens are proteins produced by tumor-specific mutations that are not present in normal tissues and are attractive targets for cancer immunotherapy because they can be recognized as foreign by the immune system.
Nykode is currently conducting a clinical study evaluating VB10.NEO: VB N-02, an open-label Phase 1b, dose-escalation study of safety and antigen-specific immune responses elicited by VB10.NEO in combination with the Roche checkpoint inhibitor atezolizumab in patients with advanced tumors and locally metastatic (NCT05018273).
About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies with a focus on the treatment of cancer and autoimmune diseases. Nykode’s modular vaccine technology specifically targets antigens to antigen-presenting cells (APCs), which have been shown to induce a broad, strong and long-lasting antigen-specific immune response in cancer, which correlates with clinical response.
Nykode’s lead product candidate is VB10.16, a therapeutic vaccine for the treatment of malignant cancers caused by HPV16 that has shown good safety and efficacy results from a Phase 2 trial for the treatment of cervical cancer. VB10.16 was expanded into multiple trials for the treatment of head and neck cancer and cervical cancer. VB10.NEO, an individual cancer neoantigen vaccine, is exclusively licensed to Genentech, a member of the Roche Group.
The Company’s partnerships include Genentech in oncology and a multi-target collaboration with Regeneron (NASDAQ: ) in oncology and infectious diseases.
Nykode is also using APC-targeted technology to create an inverse vaccine platform for potential use in autoimmune disorders, organ transplant rejection, anti-drug antibody reactions and allergies.
You can buy or sell shares of Nykode Therapeutics, Inc. on the Oslo Stock Exchange. More information about Nykode Therapeutics can be found at http://www.nykode.com.
Nykode Therapeutics, Inc.’s financial results report
This announcement and any materials distributed in connection with this announcement may contain certain forward-looking statements. By their nature, forward-looking statements involve risks and uncertainties because they reflect the company’s current expectations and assumptions about future events and conditions that may not be accurate. A number of material factors could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.
Contact for Nykode Therapeutics ASA:
Head of Investor Relations, Alexandra Deschner
Nykode Therapeutics ASA
IR@nykode.com
Nykode Therapeutics ASA
Oslo Science Park
Gaustadalléen 21
N-0349 Oslo, Norway
Source: Nykode Therapeutics ASA
